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ABSTRACT
Transient receptorpotential channelC6 (TRPC6)gain-of-functionmutations and increasedTRPC6expression in
podocytes induce glomerular injury and proteinuria. Sildenafil reduces TRPC6 expression and activity in non-
renal cell types, although the mechanism is unknown. Peroxisome proliferator–activated receptor g (PPAR-g)
is a downstream target of sildenafil in the cyclic guanosinemonophosphate (cGMP)–activated protein kinaseG
(PKG) axis. PPAR-g agonists, like pioglitazone, appear antiproteinuric. We hypothesized that sildenafil inhibits
TRPC6 expression in podocytes through PPAR-g–dependent mechanisms, thereby counteracting podocyte
injury and proteinuria. Treatment with sildenafil, the cGMP derivative 8-bromoguanosine 39,59-cyclic mono-
phosphate sodium salt (8-Br-cGMP), or pioglitazone dose-dependently downregulated podocyte injury-
induced TRPC6 expression in vitro. Knockdown or application of antagonists of PKG or PPAR-g enhanced
TRPC6 expression in podocytes and counteracted effects of sildenafil and 8-Br-cGMP. We observed similar
effects on TRPC6 promoter activity and TRPC6–dependent calcium influx. Chromatin immunoprecipitation
showedPPAR-g binding to theTRPC6promoter. Sildenafil orpioglitazone treatmentpreventedproteinuria and
the increased TRPC6 expression in rats with adriamycin-induced nephropathy and mice with hyperglycemia-
induced renal injury. Rats receiving PPAR-g antagonists displayed proteinuria and increased podocyte
TRPC6 expression, as did podocyte-specific PPAR-g knockoutmice, which weremore sensitive to adriamycin
and not protected by sildenafil. Thus, sildenafil ameliorates podocyte injury and prevents proteinuria through
cGMP- and PKG-dependent binding of PPAR-g to the TRPC6 promoter, which inhibits TRPC6 promoter activ-
ity, expression, and activity. Because sildenafil is approved for clinical use, our results suggest that additional
clinical study of its antiproteinuric effect in glomerular disease is warranted.
J Am Soc Nephrol 28: ccc–ccc, 2016. doi: 10.1681/ASN.2015080885
Sildenafil, also known as Viagra, was originally de-
veloped to treat angina pectoris and systemic hy-
pertension. However, the first clinical trials were
disappointing, and currently, sildenafil is primarily
used to treat erectile dysfunction as well as pulmo-
nary arterial hypertension. In this study, we explore
the mechanism of a potential antiproteinuric effect
of sildenafil in glomerular disease.
Sildenafil increases intracellular cyclic guanosine
monophosphate (cGMP) levels by inhibiting the en-
zyme phosphodiesterase 5A (PDE5A), which con-
verts cGMP to guanosine monophosphate.1 cGMP
is a second messenger that gives rise to numerous
(intra)cellular effects, leading to stimulation of gly-
cogenolysis, apoptosis, smooth muscle relaxation,
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and vasodilation. The raised cGMP levels also activate protein
kinase G (PKG), which can stimulate the nuclear receptor and
transcription factor peroxisome proliferator–activated receptor
g (PPAR-g). On stimulation, PPAR-g heterodimerizes with ret-
inoid X receptors and regulates gene transcription of various
target genes.2 Several PPAR-g agonists (i.e., the thiazolidine-
diones class of antidiabetic drugs, such as pioglitazone and
rosiglitazone) have been suggested to be renoprotective.3,4
One of the possible transcriptional targets of PPAR-g is the
Transient Receptor Potential Channel C6 (TRPC6), a nonspecific
calcium (Ca2+)–conducting ion channel that is expressed in pul-
monary vascular and penile corporal smoothmuscle cells but also,
renal glomerular podocytes.5,6 Gain-of-function mutations in
TRPC6 lead to FSGS, which is characterized by podocyte foot pro-
cess effacement, proteinuria, and eventually, ESRD.7,8 Importantly,
we and others have shown that, in acquired human and experi-
mental glomerular diseases, TRPC6 expression in the podocyte is
increased.9–11 Podocytes are glomerular epithelial cells covering the
outside of the glomerular capillaries with their intertwined foot
processes, thereby creating a sieve or slit diaphragm in the glomer-
ular filtration barrier. Ca2+ influx through TRPC6 activates several
pathways in the podocyte, including the deleterious feed-forward
calcineurin/NFAT pathway, which decreases expression of slit
diaphragm-associated proteins, such as nephrin, and induces
podocyte injury and eventually, proteinuria.12–14 Hall et al.15 pre-
viously showed that PKG affects TRPC6 phosphorylation at Thr69
in podocytes, which reduces TRPC6 functional channel activity.
In addition, pretreatment of podocytes with a PKG agonist or a
PDE5 inhibitor decreased TRPC6 Thr69 phosphorylation and in-
hibited TRPC6–dependent podocyte motility. Importantly, it has
been described that sildenafil, by activating PKG and PPAR-g,
affects TRPC6 expression in the pulmonary vasculature, which
is relevant to its therapeutic effect in pulmonary hypertension,
whereas a dominant negative TRPC6 mutant was recently shown
to restore erectile dysfunction in diabetic rats.5,6 We hypothesize
that sildenafil activates PPAR-g and reduces TRPC6 expression in
the podocyte, whichmay decrease proteinuria, thereby contribut-
ing to the suggested renoprotective action of sildenafil (Figure 1).
In this study, we determined whether sildenafil affects TRPC6
promoter activity, expression, and subsequently, TRPC6 channel
activity and whether this is a PPAR-g–dependent effect. In addi-
tion,we investigated if these effects also have an in vivo significance.
Elucidating these signaling processes will reveal more mechanistic
insights into sildenafil or PPAR-g agonists as therapeutic agents
that could ameliorate renal injury and proteinuria in patients.
RESULTS
PDE5A Is Expressed by Podocytes
The expression of PDE5A in podocytes, which plays a central role
in our hypothesis (Figure 1), was not previously described. Cul-
tured immortalizedmouse podocytes (MPC-5) andmouse kidney
cortexexpress PDE5AmRNA(Figure 2A).Western blot analysis of
protein extracts of MPC-5 cells and mouse cortex also revealed
PDE5A protein expression (Figure 2B). Moreover, PDE5A is ex-
pressed in glomeruli, and importantly, costaining with synapto-
podinconfirmsPDE5Aexpression inpodocytes in vivo (Figure 2C).
Sildenafil Dose-Dependently Downregulates TRPC6
Expression via PKG-1 in Injured Podocytes by Affecting
TRPC6 Promoter Activity
We addressed our proposed hypothesis (Figure 1) by exposing
adriamycin– or puromycin aminonucleoside (PAN)–injured
MPC-5 immortalized mouse podocyte cultures to different
concentrations of sildenafil or the cell-permeable cGMP–
derivative 8-bromoguanosine 39,59-cyclicmonophosphate so-
dium salt (8-Br-cGMP) with or without the PKG-1 inhibitor
KT5823. TRPC6 expression in PAN and adriamycin-treated
podocytes was increased compared with untreated control
cells, which could be dose-dependently downregulated by sil-
denafil treatment (Figure 3A). The cell-permeable cGMP de-
rivative 8-Br-cGMP also downregulated TRPC6 expression in
injured podocytes (Figure 3B). The PKG-1 antagonist KT5823
and importantly, PKG-1 knockdown (KD; 83%65% KD ver-
sus scrambled controls on the basis of quantitative PCR
[qPCR] results) prevented downregulation of TRPC6 expression
by sildenafil and 8-Br-cGMP in injured podocytes (Figure 3C).
To confirm the mRNA data and determine TRPC6 localization,
parts of the experiments were repeated, and cells were stained for
TRPC6. Injury causedTRPC6 to bemore expressed on themem-
brane compared with uninjured and injured cells treated with
sildenafil (Supplemental Figure 1). A luciferase-based TRPC6
promoter activity assay was performed to determine whether
the above-described effects were mediated by inhibition of
TRPC6 transcription. Importantly, both sildenafil (Figure 3D)
and 8-Br-cGMP (Figure 3E) inhibited TRPC6 promoter activity.
Moreover, the PKG-1 antagonist KT5823 prevented the effects of
both sildenafil and 8-Br-cGMP on TRPC6 promoter activity
Figure 1. Hypothesis that links sildenafil to TRPC6. Sildenafil inhibits
PDE5A, thereby indirectly increasing cellular cGMP levels. cGMP sig-
naling activates PKG-1 and subsequently PPAR-g, which inhibits TRPC6
transcription and expression. This leads to reduced TRPC6 channel
expression at the membrane of the podocyte, thereby reducing
TRPC6–mediated Ca2+ influx and eventually, podocyte injury in the
context of glomerular disease. We propose that this pathway can be
modulated by blocking PKG-1 with KT5823, activating PPAR-g with
pioglitazone or rosiglitazone, or inhibiting PPAR-g with GW9662.
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(Figure 3F). Evaluation of other TRPC channels in podocytes
revealed expression of TRPC1 (Supplemental Figure 2A),
TRPC2 (Supplemental Figure 2B), TRPC3 (Supplemental Figure
2C), TRPC5 (Supplemental Figure 2D), and TRPC7 (Supple-
mental Figure 2E). Apart from TRPC6, only TRPC1 expression
was downregulated by sildenafil.
Downregulation of TRPC6 Expression by Sildenafil
Leads to Reduced TRPC6–Mediated Ca2+ Influx into
the Podocyte
Subsequently, it was determined whether the reduced transcrip-
tion and expression of TRPC6 resulted in a reduced TRPC6–
mediated Ca2+ influx. Podocytes, which were stably transfected
with a scrambled or TRPC6 KD construct (89%62% KD versus
scrambled controls as determined by qPCR analysis), were pre-
treated with sildenafil and 8-Br-cGMP either with or without
cotreatment with the PKG-1 antagonist KT5823. Thereafter,
TRPC6–mediated 1-oleoyl-2-acetyl-sn-glycerolin–activated Ca2+
influx in the absence of aforementioned compounds was deter-
mined. Compared with nonpretreated control podocytes, signif-
icantly less Ca2+ influx was measured in podocytes pretreated
with sildenafil or 8-Br-cGMP, an effect that was prevented by
inhibiting PKG-1 by pretreatment with KT5823 (Figure 4A). Im-
portantly, in TRPC6 KD cells, Ca2+ influx was almost absent and
was not influenced by any pretreatment regimen (Figure 4B).
PPAR-g Agonists and Antagonists as Well as PPAR-g
KD Influence TRPC6 Promoter Activity, TRPC6
Expression, and Channel Activity
To evaluate whether PPAR-g activation is able to downregulate
TRPC6 expression, mouse podocytes were treated with pio-
glitazone and rosiglitazone to activate PPAR-g. Indeed,
pioglitzone (Figure 5A) and rosiglitazone
(Figure 5B) treatment inhibited PAN and
adriamycin-induced TRPC6 overexpres-
sion. Moreover, when uninjured podocytes
were transfectedwithPPAR-g siRNA (86%6
3% KD versus scrambled controls as deter-
mined byqPCR analysis) or treatedwith the
PPAR-g inhibitor GW9662, TRPC6 expres-
sion increased, which was additive to the
upregulation caused by adriamycin and
PAN (Figure 5C). To confirm mRNA data
and determine TRPC6 localization, parts of
the experiments were repeated, and cells
were stained for TRPC6. Injury as well as
inhibition of PPAR-g caused TRPC6 to be
more expressed on the membrane com-
pared with uninjured and injured cells
treated with pioglitazone (Supplemental
Figure 1). Accordingly, a concentration-
dependent inhibition of TRPC6 promoter
activity by pioglitazone (Figure 5D) and ro-
siglitazone (Figure 5E) treatment was evi-
dent, whereas PPAR-g antagonism with
GW9662 increased TRPC6 promoter activity (Figure 5F). Im-
portantly, using a chromatin immunoprecipitation (ChIP) as-
say, it could be shown that PPAR-g directly binds to the TRPC6
promoter using a TRPC6 promoter construct transfected into
Opossum Kidney cells (Figure 5G) as well as the endogenous
TRPC6 promoter in cultured podocytes (Figure 5H). In the
ChIP experiment concerning the endogenous TRPC6 pro-
moter, the presence of PPAR-g protein could be confirmed in
the samples pulled down with the anti–PPAR-g antibody, the
(positive control) antihistone H3, and the input using Western
blot analysis (Figure 5I). The decreased TRPC6 expression due to
PPAR-g activation resulted in reduced TRPC6–mediated Ca2+
influx into podocytes (Figure 5J). In contrast, pretreatment with
GW9662 enhanced the Ca2+ influx. Again, Ca2+ influx was
almost absent and not influenced by pioglitazone or GW9662
pretreatment in TRPC6 KD podocytes (data not shown). No
significant effects of pioglitazone and rosiglitazone treatment
on expression of TRPC1 (Supplemental Figure 2A), TRPC2
(Supplemental Figure 2B), TRPC3 (Supplemental Figure 2C),
TRPC5 (Supplemental Figure 2D), and TRPC7 (Supplemental
Figure 2E) were found.
PPAR-g Antagonist and PPAR-g Knockdown Abrogate
the Effect of Sildenafil on TRPC6 Promoter Activity,
TRPC6 Expression, and Channel Activity
To determine the suggested role of PPAR-g in the sildenafil-
and cGMP-induced inhibition of TRPC6 promoter activity,
expression, and functionality as shown above, PAN and
adriamycin-injured podocytes transfected with PKG-1, PPAR-g,
or scrambled siRNA were treated with sildenafil, 8-Br-cGMP,
pioglitazone, or rosiglitazone in combination with KT5823
or GW9662. PPAR-g KD and GW9662 treatment abolished
Figure 2. PDE5A is expressed by podocytes. RNA and protein were isolated from cultured
podocytes and renal mouse cortex; subsequently, (A) PCR and (B) Western blot were
performed to determine PDE5A expression in these samples. Glomerular PDE5A ex-
pression was confirmed by immunofluorescence staining of PDE5A. (C) Importantly,
costaining with synaptopodin showed PDE5A expression in the podocytes; merge is a
higher magnification of single-channel images. AB, antibody; NTC, no template control.
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the inhibitory effect of sildenafil and 8-Br-cGMP on TRPC6 ex-
pression in adriamycin- and PAN-injured podocytes (Figure 6A).
Importantly, activation of PPAR-g in combination with KT5823
treatment or in PKG-1 KD still podocytes downregulated TRPC6
expression after injury. Moreover, KD or inhibition of PPAR-g in
combination with adriamycin- or PAN-induced injury seemed
additive, resulting in an even higher TRPC6 expression compared
with control. To confirm mRNA data and determine TRPC6 lo-
calization, parts of the experiments were repeated, and cells were
stained for TRPC6. Injury as well as inhibition of PPAR-g caused
TRPC6 to be more expressed on the membrane compared with
uninjured cells, whereas activation of PPAR-g during inhibition of
PKG-1 led to a similar TRPC6 expression compared with unin-
jured cells (Supplemental Figure 1). In line with the above
information, the effects of sildenafil and 8-Br-cGMP on TRPC6
promoter activity were also abolished when cotreated with
GW9662 (Figure 6B). These TRPC6 transcriptional and expres-
sional changes also had functional effects, because GW9662
pretreatment completely blocked the effects of sildenafil and
8-Br-cGMP on Ca2+ influx (Figure 6C). Again, 1-oleoyl-2-acetyl-
sn-glycerolin–stimulated Ca2+ influx was virtually absent and
unaffected by any pretreatment in TRPC6 KD podocytes (data
not shown).
Podocyte-Specific PPAR-g KO Mice Show Increased
Glomerular TRPC6 Expression
To determine the in vivo role of PPAR-g expressed by the
podocyte in the regulation of TRPC6 expression, TRPC6
Figure 3. Sildenafil dose-dependently downregulates TRPC6 expression via PKG-1 in injured podocytes by affecting TRPC6 promoter
activity. Cultured podocytes, transfected with either PKG-1 or scrambled siRNA, were injured by adriamycin (ADRIA) or PAN application and
treated with different concentrations of (A) sildenafil or (B) 8-Br-cGMP (C) with or without PKG-1 antagonist KT5823, and TRPC6 mRNA
expression was determined. Opossum Kidney cells expressing a TRPC6 promoter luciferase construct were treated with the same con-
centrations of (D) sildenafil or (E) 8-Br-cGMP (F) with or without KT5823. Firefly-to-Renilla ratio was calculated and normalized for vehicle-
treated cells; n=4–8 in at least two independent experiments. Statistical significance was determined using ANOVA followed by Bonferroni
post hoc test. *P,0.05 versus control cells; #P,0.05 versus ADRIA-treated cells; $P,0.05 versus PAN-treated cells.
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expression was determined in a podocyte-specific PPAR-g
knockout (KO) mouse model.16 Importantly, glomerular
TRPC6 protein (Figure 7A) and mRNA (Figure 7B) expres-
sion was significantly increased in podocyte-specific PPAR-g
KO mice compared with wild-type littermates, which was
accompanied by increased protein expression of the podo-
cyte injury marker desmin (Figure 7C) and decreased protein
expression of the central slit diaphragm protein nephrin
(Figure 7D).
Pharmacologic Inhibition of PPAR-g in Rats Leads to
Glomerular and Podocyte Injury
To study whether pharmacologic inhibition of PPAR-g also
increases TRPC6 expression in vivo, Wistar rats were treated with
different concentrations of GW9662 (0, 0.1, 1.0, or 10 mg/kg),
andwe determinedTRPC6 expression (Supplemental Figure 3A)
and proteinuria (Supplemental Figure 3B). After these dose-
finding experiments, ratswere treatedwithvehicle or the PPAR-g
antagonist GW9662 (10 mg/kg body wt) for 6 weeks. Indeed,
immunofluorescence (Figure 8A) and mRNA expression
(Figure 8B) analysis showed that GW9662 treatment increased
glomerular TRPC6 mRNA and protein expression as well as
desmin expression (Figure 8C), whereas nephrin expression
was downregulated compared with in untreated control rats
(Figure 8D). Rats treated with GW9662 showed a significantly
increased urinary albumin-to-creatinine ratio (Figure 8E) and
IgG (Figure 8F) excretion.
Pioglitazone Treatment Prevents TRPC6
Overexpression and Podocyte Injury in Adriamycin-
Induced Nephropathy
To evaluate whether the PPAR-g agonist pioglitazone has re-
noprotective properties associated with regulation of TRPC6
expression in vivo, adriamycin nephropathy was induced in
rats, after which treatment with pioglitazone (12 mg/kg body
wt) was immediately started and continued for 6 weeks. Pio-
glitazone prevented upregulation of TRPC6 expression as de-
termined by immunofluorescence analysis (Figure 9A) and
qPCR (Figure 9B). Glomerular desmin protein expression
(Figure 9C) was also increased in adriamycin-induced ne-
phropathy animals. Accordingly, nephrin expression was re-
duced in adriamycin-treated rats and normalized when these
rats were treated with pioglitazone (Figure 9D). Adriamycin-
exposed rats had an increased urinary albumin (Figure 9E)
and IgG excretion (Figure 9F), which was remarkably amelio-
rated by pioglitazone treatment. Moreover, periodic acid–
Schiff staining revealed that adriamycin increased the number
of glomerular lesions, which was prevented by pioglitazone
treatment (Figure 9G).
Sildenafil Prevents TRPC6 Overexpression and
Podocyte Injury in the Adriamycin-Induced
Nephropathy Rat Model for FSGS
To determine whether sildenafil treatment also inhibits injury-
induced TRPC6 expression in vivo and has an antiproteinuric
Figure 4. Downregulation of TRPC6 expression by sildenafil leads to reduced TRPC6–mediated Ca2+ influx into the podocyte. Intracellular
Ca2+ concentration was determined by fura-2 ratiometry. Cultured podocytes transfected with a scrambled siRNA construct were pretreated
with sildenafil or 8-Br-cGMP with or without the PKG-1 antagonist KT5823 for 24 hours. (A) After removal of the specific media, cells were
exposed to 100 mM 1-oleoyl-2-acetyl-sn-glycerolin (OAG) to activate the TRPC6 ion channel. (B) The same experimental setup was tested in
TRPC6 KD podocytes. The arrows indicate the time points of OAG application; n=5 in two independent experiments. Statistical significance
was determined using a repeated measurement test. *P,0.05 versus vehicle-treated cells.
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Figure 5. PPAR-g agonists and antagonists as well as PPAR-g KD influence TRPC6 promoter activity, TRPC6 expression, and channel
activity. Cultured podocytes were injured by adriamycin (ADRIA) or PAN application and treated with different concentrations of the
PPAR-g agonist (A) pioglitazone or (B) rosiglitazone, and TRPC6 mRNA expression was determined. (C) In addition, TRPC6 expression
was determined in uninjured podocytes, transfected with scrambled or PPAR-g siRNA, and treated with various concentrations of the
PPAR-g antagonist GW9662. A luciferase assay was performed to determine TRPC6 promoter activity in Opossum Kidney cells treated
with (D) pioglitazone, (E) rosiglitazone, and (F) GW9662. TRPC6-to-GAPDH and Firefly-to-Renilla ratios were calculated and normalized
for vehicle-treated cells. ChIP assays were performed to determine whether PPAR-g directly binds to the TRPC6 promoter. This was
tested using (G) a promoter construct transfected into OK cells or (H) the endogenous TRPC6 promoter in cultured mouse podocytes.
Antibodies against histone H3 (H3) as positive control, PPAR-g to determine whether PPAR-g bound to the TRPC6 promoter, and IgG
as negative control were used to purify fractions of the DNA. (G and H) Hereafter, the proteins were digested, PCR was performed with
primers detecting the TRPC6 promoter, and products were put on gel. (I) Western blot analysis showed that PPAR-g was present in the
6 Journal of the American Society of Nephrology J Am Soc Nephrol 28: ccc–ccc, 2016
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effect, adriamycin nephropathy was in-
duced in rats followed by treatment with
5 mg/kg body wt oral sildenafil for 6 weeks.
Adriamycin increased glomerular TRPC6
expression as determined by immunofluo-
rescence analysis (Figure 10A) and qPCR
(Figure 10B), which was accompanied by
increased expression of desmin (Figure
10C) and a reduction of nephrin expres-
sion (Figure 10D). These expressional
changes were all normalized by sildenafil
treatment. Importantly, adriamycin treat-
ment resulted in increased urinary albumin
(Figure 10E) and IgG excretion (Figure
10F), which was significantly reduced by
sildenafil exposure. Moreover, periodic
acid–Schiff staining revealed that adriamy-
cin increased number of glomerular
lesions, which were prevented by pioglita-
zone treatment (Figure 10G).
To determine whether sildenafil alone
would deleteriously regulate TRPC6 ex-
pression or induce glomerular injury,
healthy mice were treated with sildenafil. No
difference was found between healthy mice
treated with vehicle and sildenafil in TRPC6
protein (Supplemental Figure 4A), TRPC6
mRNA(Supplemental Figure 4B), desminpro-
tein (Supplemental Figure 4C), and nephrin
protein expression (Supplemental Figure 4D).
Sildenafil Does Not Prevent TRPC6
Overexpression and Podocyte Injury
in Adriamycin-Challenged Podocyte-
Specific PPAR-g KO Mice
To determine the significance of PPAR-g in
the in vivo effect of sildenafil, we deter-
mined TRPC6 expression and renal injury
markers in adriamycin-injured vehicle- or
sildenafil-treated podocyte-specific PPAR-g
KO mice. In contrast to wild-type mice,
injury-induced glomerular TRPC6 protein
(Figure 11A) and mRNA (Figure 11B) ex-
pression was not normalized by sildenafil
input sample, in the PPAR-g–immunoprecipitated sample, and in the H3-positive control sample of the nontransfected MPC-5 cells.
Culturedpodocytes stably transfectedwith scrambled siRNAwerepretreatedwith sildenafil or 8-Br-cGMPwith orwithoutKT5823 for 24hours.
(J) After removal of the specific media, cells were exposed to 100 mM 1-oleoyl-2-acetyl-sn-glycerolin (OAG) to activate the TRPC6 ion
channel. Intracellular Ca2+ concentration was determined by fura-2 ratiometry. The arrow indicates OAG application; n=4–8, in at least two
independent experiments. Statistical significance was determined using ANOVA followed by (A–F) Bonferroni post hoc test or (J) repeated
measurement test. *P,0.05 versus vehicle-treated uninjured cells; #P,0.05 versus ADRIA-treated cells; $P,0.05 versus PAN-treated cells;
†P,0.05 versus scrambled transfected uninjured cells; ¥P,0.05 versus the GW9662 of equal concentration-treated scrambled cells;
£P,0.05 versus the GW9662 of equal concentration-treated PPAR-g KD cells; 6P,0.05 versus the ADRIA-challenged GW9662 of equal
concentration-treated cells.
Figure 6. PPAR-g antagonism abrogates the effect of sildenafil on TRPC6 promoter
activity, TRPC6 expression, and channel activity. Cultured podocytes, transfected with
scrambled, PKG-1, or PPAR-g siRNA, were injured by adriamycin (ADRIA) or PAN
application and treated with sildenafil, 8-Br-cGMP, pioglitazone, or rosiglitazone with
or without PPAR-g antagonist GW9662. (A) Subsequently, TRPC6 mRNA expression
was determined. (B) TRPC6 promoter activity was measured using a luciferase pro-
moter assay in Opossum Kidney cells treated with sildenafil or 8-Br-cGMP with or
without GW9662. Firefly-to-Renilla ratio was calculated and normalized for vehicle-
treated cells. Cultured podocytes stably transfected with scrambled siRNA were
pretreated with sildenafil or 8-Br-cGMP with or without GW9662 for 24 hours. (C) After
removal of the specific media, cells were exposed to 100 mM 1-oleoyl-2-acetyl-sn-
glycerolin (OAG) to activate the TRPC6 ion channel. Intracellular Ca2+ concentration
was determined by fura-2 ratiometry. The arrow indicates the time point of OAG
application; n=4–7 in at least two independent experiments. Statistical significance
was determined using ANOVA followed by (A and B) Bonferroni post hoc test or (C)
repeated measurement test. *P,0.05 versus vehicle-treated cells; #P,0.05 versus
ADRIA-treated cells.
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in podocyte-specific PPAR-g KO mice. Desmin expression
showed a similar pattern (Figure 11C). Nephrin expression
was increased in sildenafil-treated adriamycin-challenged
wild-type animals, whereas this was completely prevented in
podocyte-specific PPAR-g KO mice (Figure 11D). Albumin-
to-creatinine ratio was only lowered by sildenafil in adriamycin-
challenged wild-type mice but not in podocyte-specific PPAR-g
KO animals (Figure 11E).
Sildenafil Prevents TRPC6 Overexpression and
Podocyte Injury in Streptozotocin-Induced
Hyperglycemic Mice with Renal Injury
Apart from adriamycin nephropathy, we and others previously
showed that increased TRPC6 expression accompanies glo-
merular injury in the streptozotocin (STZ)–induced diabetes
model for diabetic nephropathy.11,17 To determine the protec-
tive role of sildenafil in another injury model, we used mice in
which hyperglycemia was induced by STZ (Figure 12A). STZ–
induced hyperglycemic mice were then treated with vehicle or
sildenafil. Glomerular TRPC6 protein (Figure 12B) and mRNA
(Figure 12C) expression was increased in vehicle-treated hyper-
glycemic mice compared with control normoglycemic mice.
TRPC6 expression was normalized in
sildenafil-treated littermates without
significantly altering serum glucose levels.
This was accompanied by a similar regula-
tion of desmin expression (Figure 12D). Al-
though nephrin expression was decreased
in hyperglycemic mice, it was normalized
by sildenafil treatment (Figure 12E). Albu-
min-to-creatinine ratio was increased in
hyperglycemic mice, whereas treatment of
hyperglycemic animals with sildenafil signifi-
cantly ameliorated proteinuria. (Figure 12F).
DISCUSSION
This study shows that sildenafil reduces
TRPC6promoter activity andTRPC6chan-
nel expression and thereby, prevents dele-
terious TRPC6–mediated Ca2+ influx in
cultured podocytes. In addition, it could
be shown that PDE5A is expressed by po-
docytes and that PPAR-g (ant)agonism
affects podocyte TRPC6 expression by
modulating the binding of PPAR-g to the
TRPC6 promoter. Both loss of PKG-1 or
PKG-1 inhibition and PPAR-g KD or
PPAR-g antagonism inhibited the effects
of sildenafil and cGMP on TRPC6 expres-
sion and activity in the podocyte. There-
fore, we propose a mechanism of action
in which a sildenafil-induced rise in
cGMP levels activates PKG-1 and subse-
quently, PPAR-g, which then directly binds to the TRPC6
promoter and downregulates its expression (as depicted in
Figure 1). Activation of the suggested pathway, thereby in-
hibiting TRPC6–dependent Ca2+ influx, could contribute to
podocyte viability and therefore, protect the glomerulus from
injury. Indeed, both podocyte-specific PPAR-g KOmice as well
as rats treated with a PPAR-g antagonist showed increased glo-
merular TRPC6 expression, signs of podocyte injury, and in-
creased proteinuria. Importantly, both sildenafil and pioglitazone
treatment prevented the increased TRPC6 expression in adria-
mycin nephropathy, a model for human FSGS. In addition,
sildenafil downregulated TRPC6 expression in a hyperglycemic
mouse model that induces renal injury. This was in both mod-
els accompanied by a reduction in podocyte injury and ame-
lioration of proteinuria.
Renoprotective effects of sildenafil were suggested before,
albeit mainly in an ischemia-reperfusion model.18–20 The ef-
fects of sildenafil in ischemia-reperfusion were postulated to
involve vascular effects, because dilation of afferent arterioles,
for instance, promotes a transient increase in glomerular fil-
tration in renal transplant recipients receiving a single dose of
sildenafil. However, we could not detect TRPC6 in the renal
Figure 7. Podocyte-specific PPAR-g–deficient mice show increased glomerular
TRPC6 expression. Glomerular TRPC6 (A) protein and (B) mRNA expression was de-
termined. In addition, protein expression of (C) desmin and (D) nephrin was measured
in podocyte–specific PPAR-g–deficient (KO) mice as well as their wild-type littermates.
Protein expression is depicted relative to the mean expression in wild-type mice; n=4
animals per group. Statistical significance was determined using an unpaired t test.
Ctr, control. *P,0.05 versus wild-type littermates.
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vasculature, and our study provides preclinical proof of as well
as a novel mechanism for a specific antiproteinuric effect of
sildenafil mediated by PPAR-g activation in the podocyte. Our
data particularly show that sildenafil affects TRPC6 transcrip-
tion and expression and thereby, alters TRPC6–mediated Ca2+
influx into the podocyte. A previous study by Hall et al.15
suggested that PDE5 inhibition induces phosphorylation of
TRPC6 at Thr69 and thereby, inhibits channel function di-
rectly. This could, in turn, also affect TRPC6 expression. We
have previously shown that TRPC6–dependent Ca2+ influx
into the podocyte activates the calcineurin/NFAT pathway,
which eventually increases TRPC6 expression.12 Therefore,
direct inhibition of TRPC6 channel signaling could lead to
TRPC6 downregulation via the latter mechanism. However,
in this study, we have shown that sildenafil-dependent activa-
tion of PPAR-g by PKG-1 plays a significant direct transcrip-
tional role in the downregulation of TRPC6 expression. We
could show effects of PKG-1 and PPAR-g on TRPC6–mediated
Ca2+ influx in the absence of sildenafil or 8-Br-cGMP.Moreover,
pretreatment of podocytes with sildenafil or 8-br-cGMP did not
significantly affect Ca2+ influx when combined with a PPAR-g
antagonist, which affects TRPC6 at the level of transcription.
Therefore, we conclude that, in our in vitro system, the cGMP-
PKG-PPAR-g pathway seems to be more important in down-
regulating TRPC6 expression compared with a possible indirect
effect through reduced TRPC6 channel function resulting from
Thr69 phosphorylation. However, Thr69 phosphorylation might,
that is, decrease the open probability of the TRPC6 channel in
parallel to the discussed transcriptional and expressional effects.
In this study, we did not determine TRPC6 phosphorylation,
because our main focus was to unravel the mechanism of the
suggested TRPC6 transcriptional downregulation via the cGMP-
PKG-PPAR-g pathway. A direct inhibition of TRPC6 channel
function by sildenafil could, however, still contribute to its in
vivo antiproteinuric effect by limiting the deleterious Ca2+ influx
through TRPC6. In this manner, sildenafil could successfully
interrupt deleterious TRPC6-mediated signaling in the podocyte
at multiple levels.
Sildenafil is currently used to treat pulmonary hyperten-
sion,where itsmainmechanismof actionhasbeendescribed to
reduce intracellular Ca2+ levels in pulmonary arterial smooth
muscle cells, leading to vasorelaxation in the pulmonary vas-
culature.21 Recently, it was also shown that, in these cells, sil-
denafil inhibits TRPC6 expression, which could be prevented
by application of a PKG-1 or PPAR-g inhibitor.22 In this way,
sildenafil prevented hypoxia-induced TRPC6 and TRPC1
Figure 8. Pharmacologic inhibition of PPAR-g in rats increases glomerular TRPC6 expression and leads to podocyte injury and proteinuria.
Wistar rats were treated with the PPAR-g antagonist GW9662 (10 mg/kg body wt) for 6 weeks, after which animals were euthanized, and
glomerular TRPC6 (A) protein and (B) mRNA expression was determined. In addition, protein expression of (C) desmin and (D) nephrin was
measured. Protein expression is depicted as percentage relative to the mean expression in vehicle-treated rats. In addition, (E) urinary
albumin-to-creatinine ratio (micrograms per millimolar) and (F) IgG-to-creatinine ratio (micrograms per millimolar) were assessed; n=8
animals per group. Statistical significance was determined using an unpaired t test. Ctr, control. *P,0.05 versus control rats.
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expression, which led to vasoconstriction, in pulmonary arte-
rial smooth muscle via the same cGMP-PKG-PPAR-g axis.
TRPC1 expression in podocytes was previously shown; thus,
its downregulation by sildenafil could be relevant. However,
currently, the (patho)physiologic role of TRPC1 in the podo-
cyte is unknown. In addition, we previously showed that an-
giotensin II blockade, angiotensin receptor blockade, high
glucose, and adriamycin administration, which are all relevant
in the context of this study, did not affect TRPC1 expression in
the podocyte.11 Very recently, the clinical antiproteinuric ef-
fect of PDE5A inhibition in albuminuric patients with diabe-
tes was shown in analogy to our experiments in hyperglycemic
mice.23 Our data are the first to show that the cGMP-PKG-
PPAR-g-TRPC6 pathway plays a role in the beneficial effect of
sildenafil in not only pulmonary hypertension but also, pro-
teinuric diseases.
Our in vivo data showed that treatment with the PPAR-g
agonist pioglitazone normalized TRPC6, desmin, and nephrin
expression and ameliorated proteinuria in adriamycin
nephropathy. The antiproteinuric effect of pioglitazone has
been previously shown in adriamycin nephropathy as well as
human proteinuric disease, and several hypotheses on the
podocyte-protective effect of PPAR-g were postulated.24,25
Among these were antiapoptotic effects and blockade of
angiotensin production as well as improved mitochondrial
function reducing the level of reactive oxygen species.26–29
Importantly, we and others described the role of angiotensin
and local angiotensin production by the podocyte in the reg-
ulation of TRPC6 expression during podocyte injury.12,30 Of
note, TRPC6–mediated Ca2+ influx has previously been linked
to podocyte apoptosis and reactive oxygen species produc-
tion.29,31 Thus, identification of TRPC6 as a direct PPAR-g
target in the podocyte could also provide a mechanistic link
between PPAR-g agonists and their previously described ef-
fects on oxidative stress and cell fate.
It was previously determined that the podocyte-specific
PPAR-g KOmice are particularly susceptible to podocyte injury
by adriamycin or nephrotoxic serum.16 This predisposition is
Figure 9. Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy
rat model for FSGS. ADRIA-induced nephropathy was induced in rats, after which control and ADRIA nephropathy rats were treated
with the PPAR-g agonist pioglitazone (12 mg/kg body wt) for 6 weeks. Thereafter, animals were euthanized, and glomerular TRPC6 (A)
protein and (B) mRNA expression was determined. In addition, protein expression of (C) desmin and (D) nephrin was measured. Protein
expression is depicted as percentage of vehicle-treated rats. In addition, (E) urinary albumin-to-creatinine ratio (micrograms per mil-
limolar), (F) IgG-to-creatinine ratio (micrograms per millimolar), and (G) percentage of glomerular lesions were assessed; n=8 animals
per group. Statistical significance was determined using ANOVA followed by Bonferroni post hoc test. Ctr, control. *P,0.05 versus
vehicle-treated control rats; #P,0.05 versus ADRIA–treated control rats.
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reminiscent of the apparent podocyte susceptibility that leads to
late-onset FSGS in patients with TRPC6 gain-of-function mu-
tations.7,8 The potential of PPAR-g agonists as treatment mo-
dalities for several renal diseases, such as diabetic nephropathy,
was already previously shown.32 Beneficial effects of PPAR-g
were suggested in tubular epithelial cells as well as glomerular
mesangial cells, endothelial cells, and podocytes in the context
of diabetic nephropathy.33–35 Importantly, we showed that
podocyte-specific absence of PPAR-g prevents the renoprotective
effect of sildenafil in the adriamycin nephropathy model.
Therefore, activation of PPAR-g could be crucial in the treat-
ment of glomerular diseases, such as FSGS.
In conclusion, we have shown that in vitro as well as in vivo
treatment with a PDE5 inhibitor or PPAR-g agonist downregu-
lates TRPC6 expression, reduces podocyte injury, and amelio-
rates the associated proteinuria. Amelioration of podocyte injury
by sildenafil seems to involve stimulation of cGMP- and PKG-
dependent binding of PPAR-g to the TRPC6 promoter, thereby
inhibiting TRPC6 promoter activity, TRPC6 expression, and ul-
timately, channel activity. In vivo, blocking this cGMP-PKG-
PPAR-g pathway induces proteinuria, whereas its stimulation
by sildenafil and pioglitazone treatment reduces glomerular in-
jury and proteinuria. These data identify sildenafil as a promising
novel antiproteinuric agent, which acts by inhibiting deleterious
TRPC6–mediated intracellular podocyte signaling.
CONCISE METHODS
Animal Studies
Mice, 12–14 weeks of age, with a podocyte-specific deletion of PPAR-g
were created using the NPHS2-Cre recombinase (podocin-Cre) mouse.16
Podocyte-specific disruption of PPAR-g alleles was achieved by crossing
podocin-Cre–positive mice with the B6.129S6-Ppargtm1.1Mgn/Mmmh
strain obtained from the Mutant Mouse Regional Resource Center at the
University ofMissouri (stock no. 012035-MU) on aC57BL6/J background.
Mice were challenged with adriamycin and treated for 3 weeks with vehicle
or sildenafil.Wild-type littermates were used as age-matched controls.
Hyperglycemia was induced in 12-week-old CD1 mice by a single
injection of STZ (150 mg/kg) as described before.36 A drop of tail
Figure 10. Sildenafil treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy
rat model for FSGS. ADRIA-induced nephropathy was induced in rats, after which control and ADRIA nephropathy rats were treated
with sildenafil (5 mg/kg body wt) for 6 weeks. Thereafter, animals were euthanized, and glomerular TRPC6 (A) protein and (B) mRNA
expression was determined. In addition, protein expression of (C) desmin and (D) nephrin was measured. Protein expression is depicted
as percentage of vehicle-treated rats. In addition, (E) urinary albumin-to-creatinine ratio (micrograms per millimolar), (F) IgG-to-
creatinine ratio (micrograms per millimolar), and (G) percentage of glomerular lesions were assessed; n=8 animals per group. Statistical
significance was determined using ANOVA followed by Bonferroni post hoc test. Ctr, control. *P,0.05 versus vehicle-injected control
rats; #P,0.05 versus ADRIA–treated control rats.
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blood was used to monitor glucose concentrations with the MediSense
Precision Plus Kit (Abbott Diagnostics, Melbourne, VIC, Australia).
After the development of hyperglycemia,mice were treated for 3weeks
with vehicle or sildenafil.
Adriamycin nephropathy was induced in Wistar rats (Charles
River Laboratories, Wilmington, MA), and animals were treated
with sildenafil, pioglitazone, or GW9662. After 6 weeks of treatment,
rats were housed in metabolic cages for 24 hours; thereafter, urine,
blood, and kidneys were collected. Urinary albumin, IgG, and creat-
inine concentrations were determined.
All animal procedures were approved by the Animal Ethics Com-
mittee of the Radboud University, the Institut National de la Santé et
de la RechercheMédicale Local Ethic Review Board at Paris Descartes
University, and the Sapienza University’s Animal Research Ethics
Committee (165/2016-PR) in accordance with the guidelines of the
Dutch, French, and Italian Council for Animal Care and the Euro-
pean Communities Council Directive (86/609/EEC).
Immunohistochemistry
Frozen kidney cortex was cut and stained for TRPC6 (rat;: Abcam,
Cambridge, United Kingdom; mice: Alomone, Jerusalem, Israel),
nephrin (R&D, Minneapolis, MN), synaptopodin (Progen
Biotechnik GmbH, Heidelberg, Germany), desmin, and PDE5A
(Santa Cruz). Subsequently, the mean fluorescent intensity was de-
termined as described previously.10,11
Cell Culture Studies
Conditionally immortalized mouse podocyte (MPC-5) cells were
cultured as described previously.37 Differentiated cells were injured
using adriamycin or PAN in combination with transfection with
scrambled, PPAR-g, or PKG-1 siRNA using Dharmafect (GE Life-
sciences) and treated with vehicle or indicated concentrations of sil-
denafil, pioglitazone, rosiglitazone, 8-Br-cGMP, KT5823, or GW9662
(Sigma-Aldrich, St. Louis, MO). Parts of the experiments were per-
formed in TRPC6 KD cells as described previously.11 The TRPC6
promoter activity assay was performed as described previously.10 In-
tracellular Ca2+ was visualized using fura-2 fluorescent Ca2+ as pre-
viously described.11 MPC-5 cells were fixed and stained for TRPC6.
Then, TRPC6 expression and cellular localization were studied.
ChIP
ChIP was performed according to the manufacturer’s protocol.
Opossum Kidney cells were transfected using lipofectamin with
TRPC6 promoter construct, and untransfected podocytes were
Figure 11. Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific
PPAR-g KO mice. ADRIA-induced nephropathy was induced in podocyte-specific PPAR-g KO and wild-type mice, after which they were
treated with sildenafil. Thereafter, animals were euthanized, and glomerular TRPC6 (A) protein and (B) mRNA expression was de-
termined. In addition, protein expression of (C) desmin and (D) nephrin was measured. Protein expression is depicted as percentage of
vehicle-treated mice. (E) In addition, urinary albumin-to-creatinine ratio (micrograms per micromolar) was assessed; n=3–8 animals per
group. Statistical significance was determined using ANOVA followed by Bonferroni post hoc test. WT, wild type.*P,0.05 versus
vehicle-injected control mice; #P,0.05 versus ADRIA–treated control mice.
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treated with pioglitazone, after which a ChIP was performed (Magna
ChIP A Chromatin Immunoprecipitation Kit; Upstate Millipore) using
an antibody directed against PPAR-g (Santa Cruz), an appropriate iso-
type control, and a positive control, an antibody directed against histone
H3. The enrichment of the TRPC6 promoter comparedwith the isotype
control was evaluated using real-time qPCR with specific primers
corresponding to the TRPC6 promoter region. Subsequently, an immu-
noblot of all samples was done to determine PPAR-g (Santa Cruz) ex-
pression in the input and immunoprecipitated samples.
Real-Time qPCR Analyses
RNAwas isolated fromkidney cortexor culturedMPC-5 cells for real-
time PCR. Glyceraldehyde-3-phosphate dehydrogenase was used as the
housekeeping gene.
Western Blotting
Protein extracts from kidney cortex or MPC-5 cells were resolved
by SDS-PAGE and blotted on a PVDF membrane. After blocking
and incubation with the appropriate first and second horserad-
ish peroxidase-labeled antibodies, the blot was analyzed using
chemiluminescence.
Statistical Analyses
All results are depicted as mean6SEM. Paired t test or ANOVA was
used to test for significance using SPSS software (IBM,NewYork, NY)
followed by a Bonferroni post hoc test. P values ,0.05 were consid-
ered significant (Supplemental Material).
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